clinical trial · NCT07594587
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Graft-Versus-Host Disease
brief summary
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
started
May 31, 2026
primary completion
Mar 15, 2030
completion
Mar 15, 2030
last updated
May 19, 2026
official title
Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol